Literature DB >> 2345841

The use of a run-in to enhance compliance.

J M Lang1.   

Abstract

With a run-in, potential subjects are given practice with all or part of the study protocol prior to randomization. The purpose is to exclude poor compliers from the trial and randomize only proven, good compliers. The feasibility of a run-in and the net benefit derived from that strategy depend upon the difficulty of the protocol; the availability of compliance aids during the trial; and the impact of the chosen common practices for all subjects during the run-in on the post-randomization event rates of the groups and the post-randomization blinding of study subjects to their treatment assignments. Two detailed examples of the use of a run-in are presented along with six general recommendations to guide the use of a run-in.

Mesh:

Year:  1990        PMID: 2345841     DOI: 10.1002/sim.4780090115

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  4 in total

1.  Experienced consent in geriatrics research: a new method to optimize the capacity to consent in frail elderly subjects.

Authors:  M G Rikkert; J H van den Bercken; H A ten Have; W H Hoefnagels
Journal:  J Med Ethics       Date:  1997-10       Impact factor: 2.903

Review 2.  Adaptive designs for randomized trials in public health.

Authors:  C Hendricks Brown; Thomas R Ten Have; Booil Jo; Getachew Dagne; Peter A Wyman; Bengt Muthén; Robert D Gibbons
Journal:  Annu Rev Public Health       Date:  2009       Impact factor: 21.981

3.  Application and impact of run-in studies.

Authors:  Michael Fralick; Jerry Avorn; Jessica M Franklin; Abdurrahman Abdurrob; Aaron S Kesselheim
Journal:  J Gen Intern Med       Date:  2018-02-15       Impact factor: 5.128

4.  ADD-ASPIRIN: A phase III, double-blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours.

Authors:  Christopher Coyle; Fay H Cafferty; Samuel Rowley; Mairead MacKenzie; Lindy Berkman; Sudeep Gupta; C S Pramesh; Duncan Gilbert; Howard Kynaston; David Cameron; Richard H Wilson; Alistair Ring; Ruth E Langley
Journal:  Contemp Clin Trials       Date:  2016-10-21       Impact factor: 2.226

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.